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Background: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common form of Polycystic
Kidney Disease (PKD) and occurs at a frequency of 1/800 to 1/1000 affecting all ethnic groups worldwide. ADPKD
shows significant intrafamilial phenotypic variability in the rate of disease progression and extra-renal manifestations,
which suggests the involvement of heritable modifier genes. Here we show that the PKD1 gene can act as a
disease causing and a disease modifier gene in ADPKD patients.
Methods: Clinical evaluation of a family with ADPKD was performed to diagnose and assess disease progression in
each individual. PKD1 was genotyped in each individual by targeted sequencing.
Results: Targeted screening analysis showed that the patients with ADPKD in the family had the PKD1: p.Q2243X
nonsense mutation. A more severe disease phenotype, in terms of estimated Glomerular Filtration Rate (eGFR) and
total kidney volume, was observed in two patients where in addition to the mutation, they carried a novel PKD1
variant (p.H1769Y). Other patients from the same family carrying only the (p.Q2243X) mutation showed milder
disease manifestations.
Conclusion: ADPKD shows significant intrafamilial phenotypic variability that is generally attributed to other
modifier genes. In this rare case, we have shown that a variant at PKD1, in trans with the PKD1 mutation, can also
act as a modifier gene in ADPKD patients. Understanding the molecular mechanism through which the gene exerts
its disease modifying role may aid our understanding of the pathogenesis of ADPKD.
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Autosomal dominant polycystic kidney disease (ADPKD)
is the most common renal hereditary disease affecting
one in every 800–1000 individuals worldwide [1]. It is
characterized mainly by growth of bilateral multiple
renal cysts and expansion of kidney size, in an age
related manner, leading to progressive impairment of
kidney functions, which ultimately results in end-stage
renal disease (ESRD). ADPKD patients can also develop* Correspondence: hamad.ali@hsc.edu.kw
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unless otherwise stated.extrarenal manifestations including hepatic and pancre-
atic cysts, cerebral and aortic aneurysms, cardiac valvu-
lar abnormalities and systematic hypertension [1-3].
ADPKD is genetically heterogeneous as it is caused by
mutations in either of two genes: PKD1, which is located
on chromosome 16 (49,511 bp with 46 exons) and PKD2,
which is located on chromosome 4 (70,133 bp with 15
exons). PKD1 mutations account for around 85% of the
ADPKD cases in clinically identified populations, while
mutations in PKD2 accounted for the remaining 15%
[4,5]. Phenotypes associated with ADPKD in terms of
age of onset of ESRD, associated liver disease and other
extrarenal manifestations show high levels of variabilityis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
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variability can be attributed to genic and allelic hetero-
geneity. In general, mutations in PKD1 are associated
with more severe disease and earlier mean of age at
onset of ESRD than mutations in PKD2 (54.3 years for
PKD1 and 74 years for PKD2) [7-9]. At the allelic level,
certain mutations are associated with more severe
disease phenotype than others [10]. For example, on
average, patients with truncating mutations have a
more severe disease phenotype than patients with non-
truncating mutations [7].
Several studies have suggested that functional gene
dosage plays a determining role in ADPKD manifest-
ation and severity. It has been shown that homozygous
inheritance of incompletely penetrant PKD1 alleles can
be associated with typical ADPKD manifestation and
ESRD, while heterozygous inheritance of the same
alleles was associated with a mild cystic disease. More-
over, the inheritance of an incompletely penetrant
PKD1 allele in trans with PKD1 inactivating mutation
has been associated with early onset ADPKD. These
cases suggest that dosage of the functional PKD1 pro-
tein (Polycystin-1) influences disease onset and can con-
tribute to the phenotypic variability observed in cases of
ADPKD [11-13].
Another element that adds to the complexity of
phenotypic variability in ADPKD is the involvement of
modifier genes that are suggested by the intrafamilial
phenotypic variability observed in ADPKD families
where patients share the same mutation but yet show
significant differences in disease severity and presenta-
tion [14,15]. Several studies have highlighted a possible
modifying role for a number of genes in ADPKD pa-
tients including ENOS and ACE. However, this role is
debatable as a number of other studies showed these
genes have no significant role in the disease progression,
severity and phenotypic variability [16-20]. It was also
shown that mutations in other PKD genes like PKHD1
and HNF1B when co-inherited with PKD1 or PKD2 mu-
tation can cause early onset of PKD [11]. Other studies
suggested phenotypic modifying roles for TSC2 and
DKK3 [21,22]. Identifying modifier genes that are re-
sponsible for the substantial clinical variability observed
in ADPKD across families would allow better prediction
of disease prognosis and contribute to better manage-
ment prior to onset of ESRD. It would also allow better
understanding of the molecular pathways involved in
the disease pathology which is important for the devel-
opment of potential therapies.
Here, we show that PKD1 is acting as a disease caus-
ing and disease-modifying gene. We show that a novel
PKD1 variant demonstrates a disease-modifying role in
trans with a PKD1 disease causing mutation in a family
with ADPKD.Methods
Inclusion criteria
Families with history of ADPKD were selected for the
study when individuals showed typical clinical presenta-
tion of ADPKD including multiple renal cysts and re-
duced kidney functions. The study was approved by the
joint committee for the protection of human subjects in
research of the Health Sciences Center (HSC) and
Kuwait Institute for Medical specialization (KIMS) (Ref-
erence: VDR/JC/690). Written informed consent was
obtained from all patients prior to involvement in the
study according to the laws and regulations of the joint
HSC and KIMS ethical committee. The pedigree of the
family was drawn using the Progeny drawing tool.
DNA isolation
A 10 ml blood sample was collected from each patient
by a qualified nurse at the nephrology department in
Mubarak Al-Kabir Hospital in Kuwait and processed im-
mediately. Genomic DNA was isolated from peripheral
blood using Gentra Puregene Blood Kit (Qiagen, 158467)
following the manufacturer’s protocol.
Mutation screening and classification of variants
Mutations were screened in the proband of the family by
locus specific amplification of PKD1 and direct sequen-
cing of exonic and flanking intronic regions of PKD1 and
PKD2 [4]. Segregation was tested by sequence analysis of
the relevant genomic fragments in family members. The
significance of missense variants was assessed using the
ADPKD Mutation Database http://pkdb.mayo.edu, multi-
sequence alignments and substitution assessment tools:
SIFT, PolyPhen2 and Align GVGD, as previously de-
scribed [12,13].
Clinical evaluation
Clinical evaluation was performed on individuals at risk,
where at least a parent or a sibling showed typical ADPKD
manifestations. Individuals who showed negative results in
mutation screening were also clinically evaluated to con-
firm their disease status, clinical results confirmed muta-
tion screening. Results not shown.
Abdominal ultrasound
All individuals except those with kidney transplants were
instructed to fast 4–6 hours prior to abdominal ultra-
sound examinations which was performed on using logic
7 GE machine with curvilinear 3.5 MHZ probe. Multiple
positions were used to assess the abdominal structures,
initially supine and then lying on both sides. Focused
ultrasound was performed to assess both kidneys, and
the liver and pancreas. Initially each kidney was assessed
in multiple views. The presence or absence of cysts was
examined and the exact number recorded when the cyst
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cyst number exceeded 20 in each kidney it was recorded
as >20. Each kidney volume was calculated following the
formula: ([Antero-posterior X Bipolar X Side-side diam-
eters]/2) automatically by the machine and expressed in
cubic centimeters (cc). Total kidney volume was calcu-
lated and height-adjusted total kidney volume (htTKV)
expressed in cubic centimeters per meter (cc/m). Liver
and pancreas were also screened for presence or absence
of cysts.
Renal function test
A 5 ml blood sample was taken from all individuals for
Renal Function Test (RFT). The test was performed in
the main laboratory at Mubarak Al-Kabir Hospital in
Kuwait. Serum Creatinine levels were determined for
each patient in μmol/l. Another 5 ml blood sample was
taken from all individuals to determine serum Cystatin
C levels using Human Cystatin C Quantikine ELISA Kit
(DSCTC0, R&D systems). The test was performed accord-
ing to manufacturer’s protocol in the laboratories of the
MLS Department in Faculty of Allied Health Sciences in
Kuwait University. Blood samples were centrifuged at
2000 rpm for 10 minutes to isolate the serum. 100ul of
assay diluent was added to each well and then 50 ul of
standard, control, and sample were added to each well
and then covered and incubated for 3 hours at 2–8°C.
Wells were aspirated and procedure repeated for a total
of four washes. 200ul of cold Cystatin C conjugate was
added to each well, and incubated for 1 hour at 2–8°C.
Wells were aspirated and washed 4 times, 200ul of sub-
strate solution was added to each well and incubated for
30 minutes at room temperature for one hour. Stop So-
lution (50 μL) was added to each well and the opticalFigure 1 Pedigree of the ADPKD family showing the PKD1 genotypedensity was determined using a microplate reader set to
450 nm.
Estimated Glomerular Filtration Rates (eGFR) was cal-
culated using the CKD-EPI CREATININE-CYSTATIN C
(2012) equation developed by Inker et al. [23]. Calculations
were performed using the GFR calculator provided on The
National Kidney Foundation website www.kidney.org.
Results
Genetic analysis
The family pedigree demonstrates the typical pattern of
inheritance seen in families with ADPKD (Figure 1).
Twenty-eight family members were enrolled in the
study representing four generations. Locus-specific PCR
and Sanger sequencing revealed that a PKD1 mutation
(p.Q2243X) segregates with the disease in the studied
family that generally showed typical ADPKD manifesta-
tions. p.Q2243X (c.6727C > T) is a known nonsense
mutation located in exon 15 of PKD1. Individuals II-3,
III-6, III-7 and IV-2 carried a novel PKD1 variant
(p.H1769Y; c.5305C > T; exon 15). Histidine 1769 is
invariantly conserved in orthologs of the PKD1 protein,
polycystin-1, to fish, except in frog where it matches the
substitution to tyrosine (Figure 2B). Histidine 1769 is
found within PKD Repeat XII and histidine is the most
commonly found residue at this position in other PKD
Repeats. Altogether we scored the variant as of Indeter-
minate significance [4]. Individuals III-6 and III-7 carried
both the mutation (p.Q2243X) and the novel variant
(p.H1769Y) (Figure 1).
The variant effect was evaluated using prediction tools
including Polyphen-2, SIFT and Mutation taster (Table 1).
Scores from Polyphen-2 and SIFT suggested that the vari-
ant has a benign effect while the Grantham Matrix Scoreof each member along with age and onset of ESRD.
Figure 2 Inheritance of PKD1 novel variant (p.H1769Y) and mutation (p.Q2243X). (A) Renal ultrasound analysis of patients inheriting the
PKD1 novel variant (p.H1769Y) and mutation (p.Q2243X). Patient (II-3) had normal kidney size with a total of 7 renal cysts. Patient (II-4) showed
extremely enlarged kidneys with multiple renal cysts and a GFR of 25 mL/min/1.73 m2 at the age of 52. Patients (II-6) showed extremely enlarged
kidneys with multiple renal cysts and reached renal failure at the age of 29. Patient (II-7) showed extremely enlarged kidneys with multiple cysts
at the age of 25. White arrows showing large cysts (B) Multi sequence alignment of polycystin-1 orthologs showing conservation of p.H1769.
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Clinical evaluation
Among the 28 family members, the 12 individuals that
carried the PKD1 mutation (p.Q2243X) showed typical
ADPKD manifestations including renal cysts, and renal
enlargement in all but the one case where the data was
unavailable (Table 2). Five patients had already reached
ESRD at the time the study was performed, and one other
had a significant decline in eGFR. Patient (III-6), who car-
ries both the mutation and the novel variant (p.H1769Y),
showed more severe disease than the rest of the family as
he reached ESRD at the age of 29 years old. He inherited
the mutation from his mother (II-4) who is 52 years old
and with Chronic Kidney Disease (CKD) stage 4. The
average onset of ESRD of the patients carrying the mu-
tation alone was 52 years old.Table 1 Novel PKD1 variant effect prediction analysis
Gene Variant DNA Variant protein Genotype Conser
(Yes/N
PKD1 c.5305C > T p.H1769Y Heterozygous Yes
aScore range 0–1.0, 1.0 is more damaging.
bScore range from 0 to 1.0. Scores ≤0.05 indicate damaging effect , scores >0.05 ind
cScore range 0–215. Higher score predicts more significant impact. The Grantham M
structure and function.In the family, the two patients (III-6 and III-7) carry-
ing both the mutation (p.Q2243X) and the novel variant
(p.H1769Y) had larger kidneys than other patients of
similar age (Table 2, Figures 2 and 3A). Patient (III-6)
had htTKV of 1362.6 cc/m at the time of ESRD (29 years)
while patient (III-7) had htTKV of 1344.1 cc/m by the age
of 25, although his renal function was in the normal range
(Figure 3B). Renal ultrasound analysis of patient II-4
showed numerous cysts of different sizes with the lar-
gest detected measuring 5.5 cm X 4 cm on the left kid-
ney at its lower pole, all with thin walls and no septation
(Figure 2A). Patient III-6 showed numerous cysts of
varying sizes, some of which had fine internal septation.
Patient III-7 showed numerous renal cysts with various
sizes with the largest detected on right kidney measur-
ing 2.6 cm X 2.4 cm. Interestingly, individual (II-3) who
harbors only the novel variant showed normal kidney
volume and function but had a total of 7 renal cysts atved
o)
Polyphen-2
Scorea
SIFT scoreb The Grantham
Matrix scorec
Novel
(Yes/No)
0.022 0.25 83 Yes
icate tolerated effect.
atrix Score predicts the impact of amino acid substitution on the protein
Table 2 Clinical and genetic evaluation of family members
Patient
code
Age on
the day
(years)
Gender Number of cysts GFR (mL/min/
1.73 m2)
ESRD
onset
(years)
htTKV
(cc/m)
Renal
transplant
Mutation Variant
Kidneys Liver Pancreas
I-2 Deceased F >40 0 0 - 58 - Yes Q2243X -
II-2 57 F >40 0 0 - 47 - Yes Q2243X -
II-3 58 M 7 0 0 94 - 312.5 No - H1769Y
II-4 52 F >40 0 0 25 - 1742.1 No Q2243X -
II-8 56 M >40 0 0 - 45 - Yes Q2243X -
II-9 58 F >40 0 0 - 58 - Yes Q2243X -
III-2 27 M >40 0 0 85 - 865.4 No Q2243X -
III-3 23 M 11 0 0 109 - 359.2 No Q2243X -
III-6 30 M >40 0 0 6 29 1362.6 No Q2243X H1769Y
III-7 25 M >40 0 2 91 - 1344.1 No Q2243X H1769Y
III-13 21 M 23 0 0 109 - 491.7 No Q2243X -
III-14 17 M >40 0 0 112 - 597.7 No Q2243X -
IV-1 4 F 2 0 0 130 - 130 No Q2243X -
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kidney had 2 small cysts with less than 1 cm at max-
imum diameters and one large midpolar cyst measuring
4.5 cm X 4.25 cm. The right kidney had 4 cysts, one is
relatively large of about 3 cm X 2.4 cm while the rest
are small with less than 1 cm at maximum diameters.
All cysts noted are of thin wall with no internal sept-
ation (Figure 2A).
Discussion
ADPKD shows a high degree of phenotypic variability
between patients due to genic and allelic heterogeneity,
and environmental influences. Involvement of modifier
genes, suggested by intrafamilial phenotypic variabil-
ity, adds more complexity to the genotype-phenotype
correlation in ADPKD [2]. Identifying those modifier
genes and understanding how they influence disease
phenotype not only will improve disease prognosis
and management but it will also aid the development
of potential therapies.Figure 3 Correlation between height-adjusted total kidney volume (h
eGFR (C). The patients carrying the mutation and novel variant had larger
while one of the patients with both variants had ESRD. The patient with juIn this study, we identified a novel PKD1 variant
(p.H1769Y) that demonstrated a disease-modifying role,
in trans with the PKD1 truncating mutation, in ADPKD
patients. The variant is at a well-conserved histidine,
which is replaced by tyrosine, a non-conservative change,
which suggest that this position is important for proper
protein function (Figure 2B). To evaluate the effect of the
novel variant on the disease severity and progression, pa-
tients were clinically evaluated using ultrasound to exam-
ine cysts and total kidney volume and by measuring GFR
using creatinine and cystatin C serum levels. Overall,
our results showed that renal volume expansion was as-
sociated with declined renal functions and older age in
the examined ADPKD family, a pattern normally seen
in families with ADPKD (Figure 3) [24-26].
To evaluate the effect of the novel variant on kidney
functions, we first examined the individual who carries
only the (p.H1769Y) variant, a 58 years old male (II-3).
Ultrasound examination revealed that patient (II-3) had
normal kidney volume with a total of seven renal cyststTKV) or eGFR and age, (A) and (B), plus correlation of htTKV and
kidney volume than patients of the same age carrying the mutation,
st p.H1769Y had normal sized kidneys and normal eGFR.
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Finding seven cysts by ultrasound in an individual of
58 years would be unusual and meet the criteria for a
diagnosis of ADPKD if they had a positive family history
[27]. In this case as they do not have a family history of
ADPKD, generally the more stringent criteria of 10 cysts
per kidney would be applied [28], but despite not meet-
ing that threshold the finding of seven cysts suggests
that p.H1769Y is of some phenotypic significance.
To further evaluate the possible disease modifying role
of the novel variant, we clinically evaluated and compared
the disease progression in patients carrying both the mu-
tation (p.Q2243X) and the novel variant (p.H1769Y) to
patients carrying only the mutation. Patient (III-6) reached
ESRD at the age of 29, 23 years earlier than average ESRD
onset in the family indicating a more severe disease
progression. Additionally, his kidneys were extremely
enlarged (htTKV 1362.6 cc/m) in comparison with pa-
tients in the same age group carrying only the mutation
(III-2 and III-3) (Table 2 and Figure 3A). The other patient
carrying both the variant and mutation (III-7) although
showing normal kidney functions at the age of 25 (eGFR
91 mL/min/1.73 m2), his kidneys were also extremely en-
larged (htTKV 1344.1 cc/m) in comparison to patients in
the same age group carrying only the (p.Q2243X) muta-
tion (III-2 and III-3) (Table 2 and Figure 3A).
Serum creatinine and cystatin C levels are elevated at
late stages of the PKD and therefore GFR does not rep-
resent a sensitive tool to monitor the disease progres-
sion. However, kidney volume enlargement reflecting
cysts development and growth appears to be a continu-
ous process throughout the course of the disease and
therefore has been proposed as an indicator to disease
severity and progression even before GFR changes can
be detected [24-26]. This suggests severe disease in pa-
tient (III-7) despite stable GFR at the age of 25.
Variant effect prediction tools like Polyphen-2 and
SIFT scored the variant as benign. While Grantham
Matrix score suggested that the variant could have an ef-
fect on protein features and splice sites. These findings
agree with our clinical findings where the novel variant,
on its own, is not ADPKD causing, as observed in indi-
vidual (II-3). However when the variant is co-inherited
with a pathogenic mutation it worsen the disease pheno-
type which suggest a possible molecular effect on pro-
tein features as suggested by the Grantham Matrix Score
(Table 1). These observations suggest that the effect of
this variant could be tolerated when co-inherited with
healthy PKD1, following recessive mode of inherence,
but when co-inherited with a disease causing mutation,
it acts as a disease modifier rather not disease causing
variant. At the molecular level, the substitution of histi-
dine to tyrosine could affect the overall stability and func-
tionality of the proteins as these two amino acids showsome different chemical properties in the form of posi-
tively charged side chain in histidine but not in tyrosine.
Around 2% of ADPKD patients show an early and
severe disease phenotype. These cases can be caused by
co-inheritance of two in trans PKD1 mutations resulting
in severe and early disease phenotype [12], or by coin-
heritance of a mutation in another cystogene [11]. These
cases sometimes can be indistinguishable clinically from
the recessive form of the disease [13]. In our case, we
propose that the novel variant (p.H1769Y) aggravated the
disease phenotype in patients (III-6 and III-7), resulting in
early onset of ESRD and renal enlargement.
Conclusion
In summary, we propose that the novel PKD1 variant
has a disease-modifying role in trans with the PKD1 mu-
tation in the studied family. Further molecular analysis
is required to investigate the molecular effect the single
amino acid substitution has on the polycystin-1 protein.
Understanding the molecular pathological basis of the
modifying role of the variant (p.H1769Y) would provide
insights to potential therapies for the disease.
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